Global /Australia /Healthcare /Drug Manufacturers - Specialty & Generic /PAR

Paradigm Biopharmaceuticals Ltd.

PAR

• ASX: PAR • Delayed

0.1700AUD -2.9%

0.1198 USD

As of 14 June 2026, Paradigm Biopharmaceuticals Ltd. has a market cap of $55.57M USD, ranking #29824 globally and #721 in Australia. It ranks #2694 in the Healthcare sector, and #154 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

29824

Country Rank

721

Sector Rank

2694

Industry Rank

154

Key Stats

Market Cap

$55.57MUSD

79.06M AUD

Enterprise Value

$51.92MUSD

73.7M AUD

Revenue (TTM)

$5.94KUSD

8.45K AUD

EBITDA (TTM)

-$27.24MUSD

-38.67M AUD

Net Income (TTM)

-$25.37MUSD

-36.09M AUD

PS Ratio

9356.2

PB Ratio

13.2

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Paul Rennie open_in_new

Founded

2014

Website

paradigmbiopharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.9%	-24%	-31%	-47%	-59%	-49%	-44%	-83%	-93%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	PAR Paradigm Biopharmaceuticals Ltd ISIN: AU000000PAR5 Shares Out.: Shares Outstanding: 576.499M¹ Shares Float: 508.834M² TV: TradingView: ASX: PAR SA: Stock Analysis: ASX: PAR YF: Yahoo Finance: PAR.AX GF: Google Finance: ASX: PAR BA: Barron's: PAR MS: Morningstar: XASX: PAR	0.1700 AUD	TV: TradingView: ASX: PAR SA: Stock Analysis: ASX: PAR YF: Yahoo Finance: PAR.AX GF: Google Finance: ASX: PAR BA: Barron's: PAR MS: Morningstar: XASX: PAR
OTC Markets (OTCMKTS / OTC) MIC: OTCM	PBIGF Paradigm Biopharmaceuticals Ltd ISIN: AU000000PAR5 Shares Out.: Shares Outstanding: 397.431M¹ Shares Float: 349.781M² TV: TradingView: OTC: PBIGF SA: Stock Analysis: OTC: PBIGF YF: Yahoo Finance: PBIGF GF: Google Finance: OTCMKTS: PBIGF BA: Barron's: PBIGF MS: Morningstar: PINX: PBIGF	0.2286 USD	TV: TradingView: OTC: PBIGF SA: Stock Analysis: OTC: PBIGF YF: Yahoo Finance: PBIGF GF: Google Finance: OTCMKTS: PBIGF BA: Barron's: PBIGF MS: Morningstar: PINX: PBIGF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Australia)

Name	Market Cap (USD) diff.	PE	Country
Neuren Pharmaceuticals Ltd. ASX: NEU	$1.09B 1.55B AUD 2K%	52.7	Australia
Actinogen Medical Ltd. ASX: ACW	$121.18M 172.39M AUD 118%	-	Australia
Clover Corporation Ltd. ASX: CLV	$112.65M 160.26M AUD 103%	18.1	Australia
Vita Life Sciences Ltd. ASX: VLS	$98.52M 140.17M AUD 77%	14.1	Australia
Beroni Group Ltd. OTCMKTS: BNIGF	$49.41M -11%	-	Australia
Next Science Ltd. ASX: NXS	$29.82M 42.43M AUD -46%	-	Australia

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$36.75B 108.92B ILS 66K%	24.2	Israel
Revolution Medicines, Inc. NASDAQ: RVMD	$29.56B 53K%	-	United States
Zhejiang NHU Company Ltd. SHE: 002001	$15.84B 107.34B CNY 28K%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.16B 1.06T INR 20K%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.04B 1.05T INR 20K%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.09B 61.6B CNY 16K%	80.6	China

chevron_leftBack